22 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27119626	18	Identification and Development of 2,3-Dihydropyrrolo[1,2-a]quinazolin-5(1H)-one Inhibitors Targeting Bromodomains within the Switch/Sucrose Nonfermenting Complex.	University of Cambridge
27115555	6	Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment Hit.	Pfizer
26572217	60	Disrupting Acetyl-Lysine Recognition: Progress in the Development of Bromodomain Inhibitors.	Genentech
25799074	65	Discovery and Characterization of GSK2801, a Selective Chemical Probe for the Bromodomains BAZ2A and BAZ2B.	Glaxosmithkline
26230603	176	Structure-Based Optimization of Naphthyridones into Potent ATAD2 Bromodomain Inhibitors.	Glaxosmithkline
26080064	141	Structure-Based Design of¿-Carboline Analogues as Potent and Specific BET Bromodomain Inhibitors.	University of Michigan
24144283	100	Structure-guided design of potent diazobenzene inhibitors for the BET bromodomains.	Icahn School of Medicine At Mount Sinai
27757418	27	Promiscuous targeting of bromodomains by bromosporine identifies BET proteins as master regulators of primary transcription response in leukemia.	University of Oxford
26702435	6	Selective targeting of the BRG/PB1 bromodomains impairs embryonic and trophoblast stem cell maintenance.	University of Oxford
32453591	70	Novel Pyrrolopyridone Bromodomain and Extra-Terminal Motif (BET) Inhibitors Effective in Endocrine-Resistant ER+ Breast Cancer with Acquired Resistance to Fulvestrant and Palbociclib.	University of Illinois At Chicago
27219867	94	Diving into the Water: Inducible Binding Conformations for BRD4, TAF1(2), BRD9, and CECR2 Bromodomains.	Genentech
30606676	83	Structure-guided discovery of a novel, potent, and orally bioavailable 3,5-dimethylisoxazole aryl-benzimidazole BET bromodomain inhibitor.	Gilead Sciences
30339381	32	Discovery of Orally Active Inhibitors of Brahma Homolog (BRM)/SMARCA2 ATPase Activity for the Treatment of Brahma Related Gene 1 (BRG1)/SMARCA4-Mutant Cancers.	Novartis Institutes For Biomedical Research
29656650	151	Discovery of Tetrahydroquinoxalines as Bromodomain and Extra-Terminal Domain (BET) Inhibitors with Selectivity for the Second Bromodomain.	University of Strathclyde
29169673	115	Design and synthesis of a biaryl series as inhibitors for the bromodomains of CBP/P300.	Wuxi Apptec
28463487	185	Structure-Based Discovery of 4-(6-Methoxy-2-methyl-4-(quinolin-4-yl)-9H-pyrimido[4,5-b]indol-7-yl)-3,5-dimethylisoxazole (CD161) as a Potent and Orally Bioavailable BET Bromodomain Inhibitor.	University of Michigan
30015487	96	Structure-Based Discovery of CF53 as a Potent and Orally Bioavailable Bromodomain and Extra-Terminal (BET) Bromodomain Inhibitor.	TBA
28268136	130	Methylpyrrole inhibitors of BET bromodomains.	Abbvie
28949521	88	Discovery of N-(4-(2,4-Difluorophenoxy)-3-(6-methyl-7-oxo-6,7-dihydro-1H-pyrrolo[2,3-c]pyridin-4-yl)phenyl)ethanesulfonamide (ABBV-075/Mivebresib), a Potent and Orally Available Bromodomain and Extraterminal Domain (BET) Family Bromodomain Inhibitor.	Abbvie
9190866	26	Nonpeptide tachykinin receptor antagonists: I. Pharmacological and pharmacokinetic characterization of SB 223412, a novel, potent and selective neurokinin-3 receptor antagonist.	Smithkline Beecham Pharmaceuticals